COMPARISON OF PROKINETIC ACTIVITY OF RANITIDINE AND NEOSTIGMINE ALONE AND IN COMBINATION- AN IN VITRO STUDY

Aroosa Ishliaq Butt, Asma Khan, Wardha Mazhar*, Qamar Uz Zaman Khan**, Imrana Maqsood

Fazaia Medical College, Islamabad Pakistan, *Foundation University Medical College, Islamabad Pakistan, **Army Medical College, Rawalpindi Pakistan

ABSTRACT

Objective: To explore the prokinetic effect of Ranitidine, to compare it with the prokinetic effect of Neostigmine and to observe the potentiating prokinetic effect of Ranitidine and Neostigmine in combination.

Study Design: Randomised controlled trial (experimental study).

Place and Duration of Study: Multi disciplinary centre, Army Medical College, Rawalpindi, from Jan to Dec 2015.

Methodology: Experiments were performed on three groups of rabbits (n=6) and Cumulative dose response curves were plotted using isolated duodenal tissue on power lab (USA). In the first two groups of experiments, cumulative concentrations of Neostigmine and Ranitidine were studied separately with neostigmine acting as a control and in the third group the potentiating effect of a fixed dose of ranitidine on neostigmine was evaluated.

Results: Neostigmine’s response was taken as 100 percent and Ranitidine’s response when compared to it came out to be 197 percent. The dose response curve of Neostigmine was shifted to the left and upwards in the presence of Ranitidine. The percent response with Neostigmine alone was taken as 100 percent and increased to 212 percent when the tissue was pre-treated with Ranitidine.

Conclusion: Our study has indicated that Ranitidine has marked prokinetic effect which is found to be greater than Neostigmine. It is also inferred that Ranitidine can potentiate the prokinetic effect of Neostigmine.

Keywords: Neostigmine, Powerlab, Prokinetic, Ranitidine.

INTRODUCTION

Gastroparesis is considered to be the main culprit of refractory/drug-resistant gastro-esophageal reflux disease (GERD). A probable 40 percent of these pharmacologically non-responders of GERD who in the end present to the surgical department for correcting the reflux are found to have causal gastroparesis. Anti-reflux surgery can cure GERD but not a chronic disorder like gastro-paresis. Gastroparesis, by itself can lead to GERD causing relaxation of the lower esophageal sphincter by distending the stomach which causes symptoms of reflux, by causing food to accumulate in the stomach which stimulates the production of gastric acid and by retrograde increase in the volume and pressure in the stomach which ultimately leads to an appreciable increase in the volume of reflux. The symptomatic overlap between gastroparesis and GERD makes it difficult to differentiate them clinically1.

Prokinetic drugs are fore front of pharmacological therapy for gastroparesis patients. These drugs expedite the propulsive passage of food via the gut by increasing the motor activity2. Conventionally, the drugs which augment the cholinergic stimulation, be it by direct or indirect measures are the mainstay of the remedial treatment. Blockers at the dopamine receptor type-2 (D2) inhibits the negative impact of dopamine on cholinergic nerve endings in the gut and thus, increases the motility of the gut. Ranitidine and similar drugs retarding acid secretion are employed in conjunction with pro-kinetic drugs for treating gastro paresis. GERD which occurs in recumbent position entails suppression of acid secretion with ranitidine as it is proven to be better than the proton pump inhibitors3.

Ranitidine has long known to be a blocker at the histamine type-2 receptors (H2) present at the parietal cell of the lining of the stomach. Histamine-
mine antagonism inhibits acid release from the stomach, prompting its use as an anti-ulcer drug. Elegant studies have revealed definite Gastroin-testinal (GI) motility enhancing activity of Ranitidine which is better than cimetidine and some known prokinetic agents4. Some studies do indicate that Ranitidine also has a pro-kinetic activity possibly by virtue of its ability to block Acetyl cholinesterase enzyme leading to decreased metabolism of acetylcholine which leads to an increase in GI motility5.

The ease of dosing, superior safety profile and less probability for drug-drug interaction has provided ranitidine an edge over its counterpart cimetidine6. Ranitidine is indicated GERD, gastric ulcers, Zollinger-Ellison syndrome and hyper-secretory states7. Ranitidine fortunately is a relatively well tolerated drug with very few side effects which include diarrhoea and headache7.

Neostigmine is a known inhibitor of the enzyme that degrades Ach which is called as acetyl cholinesterase (AchE), and thus increases levels of this neurotransmitter in the synaptic gap. The increased levels of Ach thus bind to the post synaptic acetylcholine receptors leading to increased parasympathetic stimulation8. Neostigmine promotes the motor activity of the gut by increasing the parasympathetic activity by reversibly inhibiting Ach E. Therefore it works only if the release of Ach and the function of smooth muscle are intact9.

Neostigmine is clinically used in Ogilvie’s syndrome (acute colonic pseudo-obstruction) and to treat postoperative ileus10,11. The most common adverse effects of neostigmine include cramps in the abdomen, vomiting, hypersalivation and bradycardia12.

The rationale of this study was to explore the intestinal stimulatory activity of ranitidine and to compare it with neostigmine both alone and in combination on isolated duodenal tissue of rabbits. This study will determine if the combined effect of the prokinetic neostigmine is greater when given in combination with ranitidine.

**METHODOLOGY**

This was a randomised controlled trial (experimental study) which was conducted at the multi disciplinary centre, Army Medical College, Rawalpindi and duration of the study was 01 year. Locally purchased, healthy looking rabbit’s (Oryctalagus cuniculus) of either sex, male/female, weighing around 2kg were included for this project using the consecutive sampling technique. They were made to adapt to the new atmosphere for around 8 days at animal keeping facility of Army Medical College. The conditions were standard that is, a light/dark cycle of 12 hours, temperature of 24°C and humidity level of around 60 percent. Standard food comprising carrots, choker and grain along with tap water was provided to the animals ad libitum. Ranitidine and Neostigmine (Sigma Chemical Co. USA) were purchased. All the dilutions were freshly prepared at the time of the experiments13. Ranitidine in a dose of (1.4-70 μg)14 and Neostigmine in doses of (0.08 μg-0.64 μg) were employed for the study15. Rabbits underwent fasting overnight to empty the bowels following which they were sacrificed in the morning. The small intestine was isolated by spotting the caecum16. Normal saline was poured over the intestine carefully with removal of any residual feolith. Whole of the small intestine (duodenum, jejunum and terminal ileum) was cut out and then carefully placed in Tyrode’s solution. The duodenum was identified by tracing back the small intestine after recognition of the caecum. Duodenum was cut into pieces. The duodenum was put inside the organ bath (50 ml) containing Tyrode’s solution and bubbled with 100 percent O217 and maintained at a temperature of 37 ± 2°C15. One end of the duodenum was tied to the bottom of the oxygen tube bath and the other was attached to a Research Grade Isometric Force Transducer DT-475-USA by the help of a silk thread. The isotonic duodenal muscle movements was measured by this Displacement Transducer18. Cumulative dose-response curves were constructed using enhancing concentrations of Neostigmine and Ranitidine. The third set of experiments was performed by taking a
sub-maximal dose of ranitidine for exploring the combined effects of the two. The selected fixed dose of ranitidine was allowed to react with the duodenal tissues in the organ bath and then cumulatively increasing concentrations of Neostigmine were employed to see the potential synergism between the two drugs. Each tissue was used for one particular concentration response curve to prevent desensitization. Response of neostigmine was taken as 100 percent and response of Ranitidine was compared with it.

Results are expressed as Means ± Standard Deviation. The arithmetic means of responses of contractile activity of isolated duodenum were calculated. The percent responses and percentage enhancement were derived using the Microsoft Office Excel 2013. Independent Sample t-test was applied for comparing two groups and a value of p<0.05 was considered as statistically significant.

RESULTS

Neostigmine’s response was taken as 100 percent and the response of Ranitidine compared to it was 197 percent. The dose response curve of calculated and the response of 0.32 µg was taken as 100 percent. The percent responses to other concentrations were 75, 80, 97 and 94 percent respectively.

Results group-2: Ranitidine (1.4 µg, 2.1 µg, 2.8 µg, 7.0 µg, 14.0 µg, 28.0 µg, 35.0 µg, and 70.0 µg) produced a mean ± SD of response of 0.080 ± 0.009 mV, 0.086 ± 0.009 mV, 0.092 ± 0.010 mV, 0.100 ± 0.024 mV, 0.111 ± 0.022 mV, 0.124 ± 0.034 mV, 0.136 ± 0.026 and 0.123 ± 0.019 mV respectively. The percent responses to 35 µg was determined as 100 percent and the responses to other mentioned concentrations were calculated as 59, 63, 68, 73, 82, 91, and 90 percent respectively.

Results group-3: The mean ± SD responses to cumulatively increasing concentrations of neostigmine (0.08 µg, 0.16 µg, 0.24 µg, 0.32 µg and 0.40 µg) in the presence of fixed dose (28 µg) of Ranitidine are 0.118 ± 0.022 mV, 0.121 ± 0.042 mV, 0.135 ± 0.021 mV, 0.146 ± 0.035 mV and 0.133 ± 0.024 mV respectively. The percent response for each sequential dose of neostigmine was calculated by taking the maximum response of neostigmine alone as maximum (0.069 mV) and then all

<table>
<thead>
<tr>
<th>Dose of neostigmine (µg)</th>
<th>Log Dose</th>
<th>Response on isolated duodenum (mean ± SD) (mV) n=6</th>
<th>Mean response of ranitidine and neostigmine (mean ± SD) (mV) n=6</th>
<th>Percent Response of neostigmine alone (%)</th>
<th>Percent Response of ranitidine and neostigmine (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.08</td>
<td>1.9</td>
<td>0.052 ± 0.029</td>
<td>0.118 ± 0.022</td>
<td>75</td>
<td>171</td>
<td>0.0047</td>
</tr>
<tr>
<td>0.16</td>
<td>2.2</td>
<td>0.055 ± 0.029</td>
<td>0.121 ± 0.042</td>
<td>80</td>
<td>175</td>
<td>0.0120</td>
</tr>
<tr>
<td>0.24</td>
<td>2.4</td>
<td>0.067 ± 0.029</td>
<td>0.135 ± 0.021</td>
<td>97</td>
<td>196</td>
<td>0.0066</td>
</tr>
<tr>
<td>0.32</td>
<td>2.5</td>
<td>0.069 ± 0.034</td>
<td>0.146 ± 0.035</td>
<td>100</td>
<td>212</td>
<td>0.0122</td>
</tr>
<tr>
<td>0.40</td>
<td>2.6</td>
<td>0.065 ± 0.030</td>
<td>0.133 ± 0.024</td>
<td>94</td>
<td>192</td>
<td>0.0027</td>
</tr>
</tbody>
</table>

Neostigmine was shifted to the left and upwards in the presence of Ranitidine. The percent response with Neostigmine alone was taken as 100 percent and increased to 212 percent when the tissue was pre-treated with Ranitidine.

Results group-1: Neostigmine (0.08 µg, 0.16 µg, 0.24 µg, 0.32 µg and 0.40 µg) produced a mean ± SD response of 0.052 ± 0.029 mV, 0.055 ± 0.029 mV, 0.067 ± 0.029 mV, 0.069 ± 0.034 mV and 0.065 ± 0.030 mV respectively. For all the above stated doses of the drug, the percent responses were the responses of ranitidine and neostigmine were compared with it and came out to be 171, 175, 196, 212 and 192 percent respectively.

Comparison of groups 1, 2 and 3

Response of neostigmine alone was taken as 100 percent and response of Ranitidine alone when compared with it came out to be 197 percent. The response increases to 212 percent when the two are used in combination. The mean ± SD values of groups 2 and 3 were found to be highly statistically significant (p=0.007). The per-
cent responses of group 2 when compared with group 3 were found to be significant statistically ($p<0.05$). The log dose response curve of ranitidine and neostigmine when plotted with neostigmine alone was shifted to the left and upwards as shown in fig-2.

**Figure-1: Semi log dose response curve of ranitidine.**

**Figure-2: Semi Log dose response curve of neostigmine alone (blue) compared with Log dose response curve of neostigmine when pretreated with a fixed dose of ranitidine (orange).**

**DISCUSSION**

The first group of experiment was carried out to observe the prokinetic activity of neostigmine which is an anti-acetylcholinesterase. Neostigmine produced a reversible dose dependent prokinetic response when added at cumulatively increasing concentrations of 0.08-0.40 µg. The maximum response as recorded by Power-Lab was 0.069 mV. This group served as a control for our study.

In the second group of experiments, the prokinetic activity of ranitidine was recorded by adding cumulatively increasing concentrations of the drug on isolated duodenum of rabbits. Ranitidine produced a marked increase in the amplitude of contractions of isolated duodenum at cumulatively enhancing concentrations of 10-5-10-3 M. The dose range established for these concentrations were 1.4-70 µg. Ranitidine produced a maximum response of 0.136 mV at 35 µg as recorded by a Displacement Transducer on iWorx/214. Kusano with his co-researchers anticipated ranitidine’s role in causing enhanced transmission of cholinergic activity$^{19}$. Zaid described the process by which ranitidine increases the motility of the gastrointestinal tract. According to him ranitidine increases the levels of acetylcholine by directly acting as agonists at the cholinergic receptors. It may also be by an indirect role that is by augmenting the release of acetylcholine from cholinergic nerve endings or by inhibiting the enzyme acetylcholinesterase$^{20}$. It was observed by Kounenis et al that ranitidine dose dependently enhanced the acetylcholine sensitive contractile activity of the gastrointestinal tract and the effect was more pronounced on the duodenum as compared to ileum, hence the selection of duodenum for this research project$^{14}$.

The efficacy of ranitidine as a prokinetic agent was compared with neostigmine. The mean response of ranitidine of all six experiments was 0.136 mV and was greater than the mean responses of neostigmine 0.069 mV. The response of neostigmine was taken as 100 percent and the response of Ranitidine when compared with it came out to be 197 percent. The prokinetic potential of ranitidine was found to be greater than neostigmine and our result is in accordance with a study carried out by Bortolotti and his co-workers in 1995. Bortolotti and his co-workers compared the prokinetic activity of ranitidine and neostigmine in patients of idiopathic gastroparesis and concluded that ranitidine enhanced the phase 3 motor activity of the gut independent of its cholinergic action and is thus a stronger prokinetic compared to neostigmine$^{21}$. The potential ability of ranitidine to increase the contractile effect of neostigmine was studied in the third set of experiments where a fixed dose of ranitidine enhanced the contractile effect of
neostigmine in vitro. The fixed dose of ranitidine selected was 0.8 ml of 10-4 M i.e. 28 µg. The maximum response of 0.32 µg of neostigmine when pre-treated with a fixed dose of ranitidine was increased to 0.146 mV as opposed to 0.069 mV when neostigmine was used alone. When neostigmine was added with ranitidine, the dose response curve was shifted to the left and upwards compared to the dose response curve of neostigmine alone. The percent response when neostigmine was given alone was 89 percent and was increased to 189 percent when pre-treated with ranitidine. The percentage enhancement of the contractile effect of neostigmine and ranitidine was 113 percent. Our findings revealed that the combination of neostigmine and ranitidine enhanced the gut contractility as compared to when neostigmine was used alone. According to a study conducted by Bortolotti et al, neostigmine was not found to be superior to ranitidine for the symptomatic relief of gastroparesis.

CONCLUSION

Our study concludes with the finding that Ranitidine apart from being a well-known H2 blocker also has a marked prokinetic effect. Its prokinetic efficacy is better than the signature prokinetic drug neostigmine. We also recommend that ranitidine can be more effective in gastric parietic conditions either alone or in combination with other prokinetic agents.

CONFLICT OF INTEREST

There is no conflict of interest to be declare by any author.

REFERENCES